Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and ...

About OCS-01 eye drops and the OPTIREACH® technology Leveraging Oculis’ proprietary technology, OCS-01 is an OPTIREACH® formulation of high concentration dexamethasone eye drop. It is being ...

Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary ...

OCS-01 is a high-concentration dexamethasone eye drop developed for ... DIAMOND-1 and DIAMOND-2 clinical trials evaluating OCS-01 eye drops for diabetic macular edema (DME). These pivotal ...

Cordyceps Sunshine Biotech Holdings Co., Ltd.【C.S Group】 announced a major milestone in veterinary drug development at the ...

to launch an authorized generic of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension), which treats and relieves bacterial eye infections. Harrow Inc (HROW ...

Leveraging Oculis’ proprietary technology, OCS-01 is an OPTIREACH ® formulation of high concentration dexamethasone eye drop ... addresses the main limitations of conventional eye drops by improving ...